Michael F Murray

List of Publications by Year
in descending order

88 papers	8,232 citations	87723 38 h-index	69108 77 g-index
94 all docs	94 docs citations	94 times ranked	13343 citing authors

#	Article	IF	Citations
1	Improved provider preparedness through an 8-part genetics and genomic education program. Genetics in Medicine, 2022, 24, 214-224.	1.1	18
2	Enabling Diagnostic Resulting as a New Category of Secondary Genomic Findings. Journal of Personalized Medicine, 2022, 12, 158.	1.1	0
3	Can We Manage Presymptomatic TTRÂV142I Related Risk?. JACC: Heart Failure, 2022, 10, 139-141.	1.9	1
4	Addressing the routine failure to clinically identify monogenic cases of common disease. Genome Medicine, 2022, 14, .	3.6	11
5	A Genome-First Approach to Characterize DICER1 Pathogenic Variant Prevalence, Penetrance, and Phenotype. JAMA Network Open, 2021, 4, e210112.	2.8	25
6	DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 979-988.	1.1	14
7	The intersection of genetics and COVID-19 in 2021: preview of the 2021 Rodney Howell Symposium. Genetics in Medicine, 2021, 23, 1001-1003.	1.1	6
8	DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 989-995.	1.1	43
9	An Integrated Approach to Deploy Panel-Based Pharmacogenetic Testing and Clinical Decision Support. journal of applied laboratory medicine, The, 2021, 6, 1094-1096.	0.6	0
10	Genetic screening for familial hypercholesterolemia identifies patients not meeting cholesterol treatment guidelines. Coronary Artery Disease, 2021, 32, 588-589.	0.3	1
11	Clinical and Molecular Prevalence of Lipodystrophy in an Unascertained Large Clinical Care Cohort. Diabetes, 2020, 69, 249-258.	0.3	51
12	DNA-Based Population Screening. JAMA - Journal of the American Medical Association, 2020, 323, 307.	3.8	31
13	Bringing monogenic disease screening to the clinic. Nature Medicine, 2020, 26, 1172-1174.	15.2	6
14	COVID-19 outcomes and the human genome. Genetics in Medicine, 2020, 22, 1175-1177.	1.1	49
15	Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program. Journal of Personalized Medicine, 2020, 10, 7.	1.1	16
16	Genetic evaluation of an adult. , 2020, , 21-29.		0
17	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. The Lancet Digital Health, 2019, 1, e393-e402.	5.9	49
18	Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. Circulation, 2019, 140, 42-54.	1.6	97

#	Article	IF	Citations
19	Trajectory of exonic variant discovery in a large clinical population: implications for variant curation. Genetics in Medicine, 2019, 21, 1417-1424.	1.1	14
20	Obtaining a Genetic Family History Using Computerâ€Based Tools. Current Protocols in Human Genetics, 2019, 100, e72.	3.5	7
21	Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants. Genetics in Medicine, 2018, 20, 554-558.	1.1	46
22	Profiling and Leveraging Relatedness in a Precision Medicine Cohort of 92,455 Exomes. American Journal of Human Genetics, 2018, 102, 874-889.	2.6	58
23	Parental attitudes and expectations towards receiving genomic test results in healthy children. Translational Behavioral Medicine, 2018, 8, 44-53.	1.2	15
24	Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2018, 320, 2354.	3.8	144
25	Exome Sequencingâ€“Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants. JAMA Network Open, 2018, 1, e182140.	2.8	163
26	Healthcare Utilization and Patientsâ€™ Perspectives After Receiving a Positive Genetic Test for Familial Hypercholesterolemia. Circulation Genomic and Precision Medicine, 2018, 11, e002146.	1.6	23
27	Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002237.	1.6	11
28	Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. Lancet Haematology,the, 2018, 5, e241-e251.	2.2	70
29	The Path to Routine Genomic Screening in Health Care. Annals of Internal Medicine, 2018, 169, 407.	2.0	14
30	Patient-Centered Precision Health In A Learning Health Care System: Geisingerâ€™s Genomic Medicine Experience. Health Affairs, 2018, 37, 757-764.	2.5	81
31	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. Annals of Internal Medicine, 2018, 169, 131.	2.0	0
32	Functional Invalidation of Putative Sudden Infant Death Syndromeâ€“Associated Variants in the KCNH2 -Encoded Kv11.1 Channel. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005859.	2.1	6
33	A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health. PLoS Medicine, 2018, 15, e1002631.	3.9	40
34	A Model for Genome-First Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a Large Research Cohort. American Journal of Human Genetics, 2018, 103, 328-337.	2.6	130
35	Genome-first findings require precision phenotyping. Genetics in Medicine, 2018, 20, 1510-1511.	1.1	5
36	Hereditary cancer genes are highly susceptible to splicing mutations. PLoS Genetics, 2018, 14, e1007231.	1.5	45

#	Article	IF	Citations
37	Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2017, 317, 937.	3.8	148
38	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circulation Research, 2017, 121, 81-88.	2.0	68
39	Electronic health record phenotype in subjects with genetic variants associated with arrhythmogenic right ventricular cardiomyopathy: a study of 30,716 subjects with exome sequencing. Genetics in Medicine, 2017, 19, 1245-1252.	1.1	43
40	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 211-221.	13.9	633
41	Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. American Journal of Human Genetics, 2017, 100, 895-906.	2.6	403
42	Adding Protective Genetic Variants to Clinical Reporting of Genomic Screening Results. JAMA - Journal of the American Medical Association, 2017, 317, 1527.	3.8	15
43	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FHâ„¢ patient registry. Atherosclerosis, 2017, 267, 19-26.	0.4	64
44	Defective splicing of the RB1 transcript is the dominant cause of retinoblastomas. Human Genetics, 2017, 136, 1303-1312.	1.8	8
45	The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients. Annals of Internal Medicine, 2017, 167, 159.	2.0	145
46	Medication therapy disease management: Geisingerâ€™s approach to population health management. American Journal of Health-System Pharmacy, 2017, 74, 1422-1435.	0.5	30
47	Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science, 2016, 354, .	6.0	464
48	Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science, 2016, 354, .	6.0	349
49	Genomics: Prediction, Prevention, Priorities, and Punnett. Annals of Internal Medicine, 2016, 164, 197.	2.0	0
50	A loss of function variant in CASP7 protects against Alzheimerâ€™s disease in homozygous APOE Îµ4 allele carriers. BMC Genomics, 2016, 17, 445.	1.2	26
51	Appropriateness: A Key to Enabling the Use of Genomics in Clinical Practice?. American Journal of Medicine, 2016, 129, 551-553.	0.6	7
52	Parental DNA sequence is critical family history in clinical genomics. Genetics in Medicine, 2016, 18, 675-677.	1.1	0
53	Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 374, 1123-1133.	13.9	411
54	The Geisinger MyCode community health initiative: an electronic health recordâ€“linked biobank for precision medicine research. Genetics in Medicine, 2016, 18, 906-913.	1.1	340

#	Article	IF	Citations
55	Your DNA is not your diagnosis: getting diagnoses right following secondary genomic findings. Genetics in Medicine, 2016, 18, 765-767.	1.1	22
56	â€˜Someday it will be the normâ€™: physician perspectives on the utility of genome sequencing for patient care in the MedSeqProject. Personalized Medicine, 2015, 12, 23-32.	0.8	40
57	Abstract 15754: The Prevalence of Electronic Health Record-Based Clinical Phenotypes in Patients With Pathogenetic Variants Associated With Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2015, 132, .	1.6	0
58	Vascular Ehlersâ€“Danlos syndrome, pixels, and high-definition clinical genomics. Genetics in Medicine, 2014, 16, 867-868.	1.1	1
59	Educating physicians in the era of genomic medicine. Genome Medicine, 2014, 6, 45.	3.6	11
60	Framework for development of physician competencies in genomic medicine: report of the Competencies Working Group of the Inter-Society Coordinating Committee for Physician Education in Genomics. Genetics in Medicine, 2014, 16, 804-809.	1.1	123
61	The growing role of professional societies in educating clinicians in genomics. Genetics in Medicine, 2014, 16, 571-572.	1.1	34
62	Why We Should Care About What You Get for â€œOnly $99â€•From a Personal Genomic Service. Annals of Internal Medicine, 2014, 160, 507.	2.0	7
63	The metabolic syndrome and DYRK1B. New England Journal of Medicine, 2014, 371, 784-5.	13.9	4
64	Susceptibility and Response to Infection. , 2013, , 1-24.		2
65	Comparing Electronic Health Record Portals to Obtain Patient-Entered Family Health History in Primary Care. Journal of General Internal Medicine, 2013, 28, 1558-1564.	1.3	35
66	Recurrent HERV-H-Mediated 3q13.2-q13.31 Deletions Cause a Syndrome of Hypotonia and Motor, Language, and Cognitive Delays. Human Mutation, 2013, 34, 1415-1423.	1.1	40
67	Implementing genomic medicine in the clinic: the future is here. Genetics in Medicine, 2013, 15, 258-267.	1.1	472
68	Implementing Genomic Medicine in the Clinic. Obstetrical and Gynecological Survey, 2013, 68, 621-623.	0.2	1
69	Gain-of-function mutations in the mechanically activated ion channel PIEZO2 cause a subtype of Distal Arthrogryposis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4667-4672.	3.3	193
70	A public resource facilitating clinical use of genomes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11920-11927.	3.3	194
71	Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genetics in Medicine, 2012, 14, 405-410.	1.1	149
72	Erdheim-Chester disease presenting with cutaneous involvement: a case report and literature review. Journal of Cutaneous Pathology, 2011, 38, 280-285.	0.7	34

#	Article	IF	Citations
73	Development and Validation of a Computational Method for Assessment of Missense Variants in Hypertrophic Cardiomyopathy. American Journal of Human Genetics, 2011, 88, 183-192.	2.6	73
74	Familial Risk of Cancer and Knowledge and Use of Genetic Testing. Journal of General Internal Medicine, 2010, 25, 717-724.	1.3	39
75	Insights into Therapy: Tryptophan Oxidation and HIV Infection. Science Translational Medicine, 2010, 2, 32ps23.	5.8	13
76	Risks of Presymptomatic Direct-to-Consumer Genetic Testing. New England Journal of Medicine, 2010, 363, 1100-1101.	13.9	47
77	Report of the Banbury Summit Meeting on the evolving role of the medical geneticist, February 12â€“14, 2006. Genetics in Medicine, 2008, 10, 502-507.	1.1	19
78	The Human Indoleamine 2,3-Dioxygenase Gene and Related Human Genes. Current Drug Metabolism, 2007, 8, 197-200.	0.7	43
79	Invasive Meningococcal Disease and a Need to Understand Host Genetic Susceptibility. Clinical Infectious Diseases, 2006, 43, 1434-1435.	2.9	2
80	Susceptibility to Infectious Diseases: The Importance of Host Genetics Edited by Richard Bellamy Cambridge: Cambridge University Press, 2004. 422 pp., illustrated. $95.00 (cloth). Clinical Infectious Diseases, 2005, 40, 338-339.	2.9	1
81	Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr). Blood, 2004, 103, 2401-2403.	0.6	60
82	Nicotinamide: An Oral Antimicrobial Agent with Activity against BothMycobacterium tuberculosisand Human Immunodeficiency Virus. Clinical Infectious Diseases, 2003, 36, 453-460.	2.9	100
83	Tryptophan depletion and HIV Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infectious Diseases, The, 2003, 3, 644-652.	4.6	119
84	Embryonic Stem Cell-Specific MicroRNAs. Developmental Cell, 2003, 5, 351-358.	3.1	1,073
85	siRNA-directed inhibition of HIV-1 infection. Nature Medicine, 2002, 8, 681-686.	15.2	750
86	Multicolour karyotyping. Lancet, The, 2001, 357, 1240.	6.3	3
87	Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. Nutrition, 2001, 17, 654-656.	1.1	41
88	A Proposed Approach for Implementing Genomics-Based Screening Programs for Healthy Adults. NAM Perspectives, 0, , .	1.3	30